A Case of Parkinson’s Disease Symptom Reduction with Intravenous NAD+

Simple item page
avondale-bepress-to-dspace.licensehttp://creativecommons.org/licenses/by/4.0/
avondale-bepress-to-dspace.peer_review_statusPeer reviewed before publication
avondale-bepress.abstract<p>Neurological deterioration in Parkinson’s disease (PD) and resulting motor dysfunction arises from Lewy body formation and dopaminergic neuronal death in the substantia nigra. Two factors contributing to PD-related apoptosis and subsequent motor dysfunction involve improper cellular metabolism of reactive oxygen species (ROS) and impaired mitochondrial functionality. The co-factor Nicotinamide Adenine Dinucleotide (NAD+), reduction of which has been implicated in the development of neurodegenerative disease, is a critical player in maintaining cellular redox metabolism and mitochondrial function. We present a case study of a PD patient who has become near asymptomatic through the use of intravenous (I.V.) NAD+. This report documents the patient’s initial symptom changes while receiving I.V. NAD+ over the course of eight treatment days, with two non-treatment days in between. The treatment entailed 1500 mg. I.V. NAD+ on day one, 1000 mg. I.V. NAD+ on day two, and 750 mg. I.V. NAD+ on day three. Symptoms were documented by medical staff for the next two days of non-treatment. Following this, 750 mg. I.V. NAD+ was administered on treatment days four and five, 500 mg. I.V. NAD+ on treatment days six and seven, and 750 mg. I.V. NAD+ on treatment day eight. Over the course of treatment, the patient’s hand tremors decreased to a mild level, permitting coordinated use of a pen and utensils. Hand tremors were absent on days one and six. Visual hallucinations were absent on days two through seven. To maintain tremors at a tolerable level, aftercare involved I.V. NAD+ every four to six weeks, with a daily regimen of 300 mg/ml NAD+ nasal spray. Moreover, the patient discontinued PD-related medication, thereby preventing visual hallucination side effects. Although more research on NAD+ in clinical use is needed, the evidence obtained from these symptom improvements indicates NAD+ as having the potential for clinical use in at least a subset of PD sufferers.</p>
avondale-bepress.articleid1227
avondale-bepress.authorsErin Gadol
avondale-bepress.authorsRichard F Mestayer
avondale-bepress.authorsRoss Grant
avondale-bepress.authorsYevgeniy Grigoryev
avondale-bepress.authorsSusan B Gibson
avondale-bepress.authorsMichael Happel
avondale-bepress.context-key21065387
avondale-bepress.coverpage-urlhttps://research.avondale.edu.au/nh_papers/230
avondale-bepress.document-typearticle
avondale-bepress.field.comments<p>Used by permission: the author(s).</p>
avondale-bepress.field.custom_citation<p>Gadol, E., Mestayer, R. F., Grant, R., Grigoryev, Y., Gibson, S. B., & Happel, M. (2019). A case of Parkinson’s disease symptom reduction with intravenous NAD+. <em>Case Reports and Literature Review, 3</em>(1), 100021.</p>
avondale-bepress.field.distribution_licensehttp://creativecommons.org/licenses/by/4.0/
avondale-bepress.field.embargo_date2021-01-12T00:00:00Z
avondale-bepress.field.field_of_education06 Health
avondale-bepress.field.for1109 NEUROSCIENCES
avondale-bepress.field.for_20214206 Public health
avondale-bepress.field.issue_number1
avondale-bepress.field.journalCase Reports and Literature Review
avondale-bepress.field.page_numbers100021
avondale-bepress.field.peer_reviewBefore publication
avondale-bepress.field.publication_date2019-04-05T00:00:00Z
avondale-bepress.field.staff_classificationConjoint
avondale-bepress.field.volume_number3
avondale-bepress.fulltext-urlhttps://research.avondale.edu.au/cgi/viewcontent.cgi?article=1227&amp;context=nh_papers&amp;unstamped=1
avondale-bepress.keywordsParkinson's disease
avondale-bepress.keywordsneurodegeneration
avondale-bepress.keywordsNAD+
avondale-bepress.label230
avondale-bepress.publication-date2019-04-05T00:00:00Z
avondale-bepress.publication-titleNursing and Health Papers and Journal Articles
avondale-bepress.statepublished
avondale-bepress.submission-date2021-01-12T18:53:54Z
avondale-bepress.submission-pathnh_papers/230
avondale-bepress.titleA Case of Parkinson’s Disease Symptom Reduction with Intravenous NAD+
avondale-bepress.typearticle
dc.contributor.authorHappel, Michael
dc.contributor.authorGibson, Susan B.
dc.contributor.authorGrigoryev, Yevgeniy
dc.contributor.authorGrant, Ross
dc.contributor.authorMestayer, Richard F.
dc.contributor.authorGadol, Erin
dc.date.accessioned2023-11-01T00:32:19Z
dc.date.available2023-11-01T00:32:19Z
dc.date.issued2019-04-05
dc.date.submitted2021-01-12T18:53:54Z
dc.description.abstract<p>Neurological deterioration in Parkinson’s disease (PD) and resulting motor dysfunction arises from Lewy body formation and dopaminergic neuronal death in the substantia nigra. Two factors contributing to PD-related apoptosis and subsequent motor dysfunction involve improper cellular metabolism of reactive oxygen species (ROS) and impaired mitochondrial functionality. The co-factor Nicotinamide Adenine Dinucleotide (NAD+), reduction of which has been implicated in the development of neurodegenerative disease, is a critical player in maintaining cellular redox metabolism and mitochondrial function. We present a case study of a PD patient who has become near asymptomatic through the use of intravenous (I.V.) NAD+. This report documents the patient’s initial symptom changes while receiving I.V. NAD+ over the course of eight treatment days, with two non-treatment days in between. The treatment entailed 1500 mg. I.V. NAD+ on day one, 1000 mg. I.V. NAD+ on day two, and 750 mg. I.V. NAD+ on day three. Symptoms were documented by medical staff for the next two days of non-treatment. Following this, 750 mg. I.V. NAD+ was administered on treatment days four and five, 500 mg. I.V. NAD+ on treatment days six and seven, and 750 mg. I.V. NAD+ on treatment day eight. Over the course of treatment, the patient’s hand tremors decreased to a mild level, permitting coordinated use of a pen and utensils. Hand tremors were absent on days one and six. Visual hallucinations were absent on days two through seven. To maintain tremors at a tolerable level, aftercare involved I.V. NAD+ every four to six weeks, with a daily regimen of 300 mg/ml NAD+ nasal spray. Moreover, the patient discontinued PD-related medication, thereby preventing visual hallucination side effects. Although more research on NAD+ in clinical use is needed, the evidence obtained from these symptom improvements indicates NAD+ as having the potential for clinical use in at least a subset of PD sufferers.</p>
dc.description.versionBefore publication
dc.identifier.citation<p>Gadol, E., Mestayer, R. F., Grant, R., Grigoryev, Y., Gibson, S. B., & Happel, M. (2019). A case of Parkinson’s disease symptom reduction with intravenous NAD+. <em>Case Reports and Literature Review, 3</em>(1), 100021.</p>
dc.identifier.urihttps://research.avondale.edu.au/handle/123456789/21065387
dc.language.isoen_us
dc.rights<p>Used by permission: the author(s).</p>
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/
dc.subjectParkinson's disease
dc.subjectneurodegeneration
dc.subjectNAD+
dc.titleA Case of Parkinson’s Disease Symptom Reduction with Intravenous NAD+
dc.typeJournal Article
Files
Original bundle
No Thumbnail Available
Name:
a_case_of_parkinsons_disease_symptom_reduction_with_intravenous_nad__100021.pdf
Size:
251.86 KB
Format:
Adobe Portable Document Format
Download
Collections
Nursing & Health
Lifestyle Medicine And Health Research Centre